UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 259

Sortiert nach

Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S57-S57

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessing oncologic benefit in clinical trials of immunotherapy agents

Annals of oncology, 2010-10, Vol.21 (10), p.1944-1951

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia

Gynecologic oncology, 2007-09, Vol.106 (3), p.558-566

2007

Link zum Volltext

Verfügbarkeit prüfen

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

European journal of cancer (1990), 2015-09, Vol.51, p.S721-S721

2015

Link zum Volltext

Verfügbarkeit prüfen

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S106-S107

2015

Link zum Volltext

Verfügbarkeit prüfen

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

European journal of cancer (1990), 2015-07, Vol.51, p.e24-e24

2015

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Link zum Volltext

Verfügbarkeit prüfen

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of oncology, 2019-04, Vol.30 (4), p.582-588

2019

Link zum Volltext

Verfügbarkeit prüfen

71IN - Anti CTLA4 and Predictive Biomarkers

Annals of oncology, 2012-09, Vol.23, p.ix46-ix46

Weber, J.S.

2012

Link zum Volltext

Verfügbarkeit prüfen

Anti CTLA4 and Predictive Biomarkers

Annals of oncology, 2012-09, Vol.23, p.ix46

Weber, J.S.

2012

Link zum Volltext

Verfügbarkeit prüfen

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

European journal of cancer (1990), 2014-11, Vol.50, p.48-49

2014

Link zum Volltext

Verfügbarkeit prüfen

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

The New England journal of medicine, 2016-11, Vol.375 (19), p.1845-1855

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

Annals of oncology, 2016-03, Vol.27 (3), p.434-441

2016

Link zum Volltext

Verfügbarkeit prüfen

The mutagenic action of N-ethyl-N-nitrosourea in the mouse

Mammalian genome, 2000-07, Vol.11 (7), p.478-483

2000

Link zum Volltext

Verfügbarkeit prüfen

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Annals of oncology, 2013-08, Vol.24 (8), p.2174-2180

2013

Link zum Volltext

Verfügbarkeit prüfen

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Annals of oncology, 2014-11, Vol.25 (11), p.2277-2284

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Ti/Si and Ti/TiN/Si interlayers on the structure, properties, and tribological behavior of an a-C film deposited onto a C17200 copper-beryllium alloy

Surface & coatings technology, 2022-07, Vol.441, p.128561, Article 128561

2022

Link zum Volltext

Verfügbarkeit prüfen

1314PD - Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Annals of oncology, 2019-10, Vol.30, p.v535-v535

2019

Link zum Volltext

Verfügbarkeit prüfen

Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Annals of oncology, 2019-10, Vol.30, p.v535

2019

Link zum Volltext

Verfügbarkeit prüfen

1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma

Annals of oncology, 2023-10, Vol.34, p.S657-S658

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

Annals of oncology, 2023-10, Vol.34, p.S1288-S1289

2023

Link zum Volltext

Verfügbarkeit prüfen

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

Annals of oncology, 2021-09, Vol.32, p.S865-S866

2021

Link zum Volltext

Verfügbarkeit prüfen

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

Annals of oncology, 2021-09, Vol.32, p.S869-S869

2021

Link zum Volltext

Verfügbarkeit prüfen

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)

Annals of oncology, 2022-09, Vol.33, p.S904

2022

Link zum Volltext

Verfügbarkeit prüfen

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Annals of oncology, 2022-09, Vol.33, p.S935-S936

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 259

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(65)
Physics
(50)
Physical Sciences
(47)
Humans
(36)
Animals
(35)
Biological And Medical Sciences
(33)
Technology
(31)
Female
(24)
Materials Science
(19)
Male
(17)
Medical Sciences
(17)
Fundamental And Applied Biological Sciences. Psychology
(16)
Oncology
(15)
Chemistry
(14)
Agriculture
(11)
Environmental Sciences
(11)
Exact Sciences And Technology
(11)
Hematology, Oncology And Palliative Medicine
(11)
Materials Science, Multidisciplinary
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy

Assessing oncologic benefit in clinical trials of immunotherapy agents

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

71IN - Anti CTLA4 and Predictive Biomarkers

Anti CTLA4 and Predictive Biomarkers

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

The mutagenic action of N-ethyl-N-nitrosourea in the mouse

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Effect of Ti/Si and Ti/TiN/Si interlayers on the structure, properties, and tribological behavior of an a-C film deposited onto a C17200 copper-beryllium alloy

1314PD - Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Suchergebnisse filtern